Context: Inflammation is a potential mechanism linking obesity and cardiometabolic risk. Limited data on inflammatory markers in metabolically healthy obese and nonobese individuals exist.
O besity promotes insulin resistance and the development of metabolic syndrome (MetS), type 2 diabetes mellitus, and cardiovascular disease (CVD) (1, 2) , leading to increased risk of premature death. However, not all obese subjects are at increased cardiometabolic risk; a proportion are considered to be metabolically healthy obese (MHO) (3) . Similarly, not all nonobese individuals present a healthy metabolic profile. Unlike metabolically unhealthy obese (MUO) individuals, the MHO phenotype may exist in the absence of metabolic abnormalities such as insulin resistance, dyslipidemia, and hypertension (4) . Insulin resistance and obesity-associated inflammation are characterized by a low-grade but chronic inflammatory state (5) . The National Cholesterol Education Program Adult Treatment Panel III recognized a proinflammatory state as an important MetS characteristic, and accumulating evidence identifies inflammation as a potential mechanism linking adipose tissue expansion and cardiometabolic risk (5) . Therefore, studying metabolically healthy and unhealthy obese and nonobese individuals could provide important insights into the inter-relationships between inflammation, metabolic health, and obesity.
Whether inflammation accounts for the metabolic differences observed between metabolically healthy and unhealthy individuals is relatively unknown. Several studies have reported more favorable inflammatory status among MHO subjects (6 -10) . In contrast, Wildman et al (11) reported that, despite not finding increased 10-year risk of cardiovascular disease among metabolically healthy overweight/obese women, these subjects still displayed abnormal levels of inflammatory markers. These conflicting findings may be accounted for by differences in ethnicity and age group, small subject numbers in some studies, and limited inflammatory profiling, together with different metabolic health criteria being used to define MHO. Evidence suggests that MHO individuals may account for as much as 35% of the obese population (12, 13) . However, prevalence estimates vary widely due to the lack of consensus regarding how to define metabolic health (14, 15) . Not all metabolic health definitions include insulin resistance (6, 16) , whereas others consider inflammatory markers (4) , making comparisons between studies difficult. A recent comparative study investigating the distribution of a limited number of proinflammatory cytokines according to different definitions of MHO concluded that the associations between inflammatory markers and MHO are definition dependent (17) . Therefore, the main objectives of this paper are to examine a larger range of proinflammatory cytokines, adipocytokines, acute-phase response proteins, coagulation factors, and white blood cell (WBC) count across a range of metabolic health definitions to comprehensively investigate to what extent differences between metabolically healthy and unhealthy obese and nonobese male and female adults are explained by inflammatory status.
Subjects and Methods

Study design and subject recruitment
The Cork and Kerry Diabetes and Heart Disease Study (Phase II) was a single center, cross-sectional study conducted between 2010 and 2011 (18) . A population representative random sample was recruited from a large primary care center in Mitchelstown, County Cork, Ireland (Mitchelstown cohort). Full details have been published elsewhere (18) , but in brief, Mitchelstown cohort participants were randomly selected from all registered attending patients in the 50-to 69-year age group. In total, 3807 potential participants were selected from the practice list. After exclusion of duplicates, deaths, and ineligibles, 3043 were invited to participate in the study, and of these, 2047 Caucasian individuals (49.2% male) completed the questionnaire and physical examination components of the baseline assessment (response rate, 67%). Ethics committee approval conforming to the Declaration of Helsinki was obtained from the Clinical Research Ethics Committee of University College Cork. All participants provided written informed consent. After exclusion of missing body mass index (BMI) data and subjects with a history of recent infections, the remaining 2040 participants were used in the analyses.
Clinical and anthropometric data
All participants attended the clinic in the morning after an overnight fast (minimum 8 h). Fasting blood samples were taken on arrival. Participants then completed a General Health Questionnaire (GHQ) and the International Physical Activity Questionnaire (IPAQ). The presence of CVD was obtained from the GHQ by asking study participants if they had been diagnosed with any 1 of the following 7 conditions: heart attack (including coronary thrombosis or myocardial infarction), heart failure, angina, aortic aneurysm, hardening of the arteries, stroke, or any other heart trouble. Subjects that indicated a diagnosis of any 1 of these conditions were classified as having CVD. Diabetes was defined according to the American Heart Association guidelines of fasting plasma glucose (FPG) Ն7 mmol/L or doctor-diagnosed diabetes. Blood pressure was measured according to the European Society of Hypertension Guidelines using an Omron M7 Digital BP monitor (Omron Healthcare, Inc) on the right arm, after a 5-minute rest in the seated position. The average of the second and third measurements was used for analyses. Hypertension was defined as average systolic blood pressure (SBP) Ն140 mm Hg or diastolic blood pressure (DBP) Ն90 mm Hg or being on hypertensive medication. Anthropometric measurements were recorded with calibrated instruments according to a standardized protocol. Body weight was measured in kilograms without shoes, to the nearest 100 g, using a Tanita WB100MA weighing scale (Tanita Corporation). Height was measured in centimeters to 1 decimal place using a Seca Leicester height gauge (Seca). Waist circumference (defined as midway between the lowest rib and the iliac crest) was measured in centimeters to 1 decimal place using a Seca 200 measuring tape (Seca). The average of 2 measures was used for analyses. BMI was calculated, and individuals with a BMI Ն30 kg/m 2 were defined as obese.
Lifestyle data
Physical activity levels were assessed using the short form IPAQ (19) , which provided information on frequency, duration, and intensity of physical activity. Smoking status was defined as never, former, and current smokers. Alcohol consumption included questions based on weekly intake to define never, moderate, and heavy drinkers and whether individuals exceeded current recommendations. Total dietary intake, including fish and dietary fat consumption, was assessed using a modified version of the self-completed EPIC food frequency questionnaire validated for use in the Irish population, which was used in the Cork and Kerry phase 1 study (20) .
Biological analyses
Plasma and serum were prepared from fasting blood samples from each subject. FPG, serum total, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglyceride levels were measured by the Cork University Hospital Biochemistry Laboratory using fresh blood samples. FPG concentrations were determined using a glucose hexokinase assay, and serum lipids were analyzed using enzymatic colorimetric tests (Olympus Life and Material Science Europa Ltd.) on an Olympus 5400 automatic analyzer (Olympus Diagnostica Gmbh). Serum insulin, C-reactive protein (CRP), TNF-␣, IL-6, adiponectin, leptin, resistin, and plasminogen activator inhibitor-1 (PAI-1) were determined using a biochip array system (Evidence Investigator; Randox Laboratories). Complement component c3 (C3) was determined by immunoturbidimetric assay (Rx Daytona; Randox Laboratories). Homeostasis model assessment, a measure of insulin resistance, was calculated as: (fasting plasma glucose ϫ fasting serum insulin)/22.5. WBC counts were determined by flow cytometry technology as part of a full blood count by the Cork University Hospital Hematology Laboratory using fresh blood samples.
Determination of metabolic health status
Subjects were classified according to their BMI as obese (BMI Ն 30 kg/m 2 ) and nonobese (BMI Ͻ 30 kg/m 2 ). Metabolic health status was defined using a selection of 5 existing metabolic health definitions based on a range of cardiometabolic abnormalities (4, 6, 16, 21) (Table 1 ). In addition to participants with MHO, MUO, metabolically healthy nonobese (MHNO), and metabolically unhealthy nonobese (MUNO) individuals were included in the current analysis.
Statistical analysis
Statistical analysis was conducted using PASW Statistics version 18.0 for Windows (SPSS Inc). Continuous variables are expressed as means Ϯ SEM, and categorical variables as percentages. Inflammatory markers were assessed for normality of distribution, and skewed variables were normalized by log 10 transformation as appropriate. Differences between groups were analyzed by independent t tests or Mann Whitney U tests for continuous variables and by 2 test for categorical variables. Logistic regression was used to determine associations between inflammatory status (categorized as below and above median level for each biomarker) and metabolic health among obese and nonobese subjects. Multivariate logistic regression analysis was performed using age, gender, physical activity, smoking status, and alcohol consumption. For all analyses, a P value Ͻ.05 was considered significant.
Results
Clinical characteristics and lifestyle factors
Subject numbers in each metabolic health by BMI category according to each metabolic health definition are presented in Figure 1 . Clinical characteristics and lifestyle factors are shown in Supplemental Table 1 (published on The Endocrine Society's Journals Online web site at http:// jcem.endojournals.org). MHO participants were generally a similar age to the MUO subjects, with the exception of MHO defined by Karelis and Meigs A, whereas the MHNO individuals were younger compared to the MUNO participants. Both the MHO and MHNO subjects were less frequently male than their unhealthy counterparts. Prevalence of CVD and type 2 diabetes mellitus was generally lower among the metabolically healthy sub- jects, with some definition-dependent findings. With the exception of MHO defined by Meigs B, no differences in hypertension estimates were noted. Examination of dietary intake and lifestyle behaviors including physical activity, smoking, and alcohol behavior revealed few differences.
Inflammatory profiles according to metabolic health status by BMI category
Concentrations of acute-phase response proteins, proinflammatory cytokines, adipocytokines, coagulation factors, and WBC counts of the study population according to metabolic health status by BMI category are presented in Table 2 . Associations between inflammatory markers and metabolic health phenotypes were dependent on which definition was used to identify metabolic health status. However, according to most definitions, MHO and MHNO individuals presented with lower C3, CRP, IL-6, TNF-␣, and PAI-1 concentrations; higher adiponectin levels; and reduced WBC count compared to their metabolically unhealthy counterparts.
Inflammatory profiles of the metabolically healthy phenotype among obese subjects Table 3 presents the odds ratios (ORs) for the MHO among the Mitchelstown participants according to inflammatory status. Obese individuals with lower C3 concentrations (below the median) were approximately 2-3.5 times more likely to present with metabolic health classified by all definitions (Figure 2 ). CRP levels in the bottom 50th percentile were also positively associated with metabolic health defined by Meigs B and Wildman. Subjects with elevated adiponectin levels (above median) had 2. 
Inflammatory profiles of the metabolically healthy phenotype among nonobese subjects
Among the nonobese subjects (Table 4) , the odds of being metabolically healthy were greater for individuals with lower levels of C3 ( Figure 2 ) and PAI-1 (ORs, 1.5-2.9) and higher adiponectin concentrations (ORs, 1.7-2.5) for all metabolic health definitions except AguilarSalinas et al (6) . CRP levels in the bottom 50th percentile were also positively associated with MHNO defined by Aguilar-Salinas, Meigs B, and Wildman. Lower IL-6 concentrations were associated with approximately 1.5 times greater odds of metabolic health defined by Meigs B and Wildman. The findings for leptin and the ratio of leptin to adiponectin were similar, with increased odds of presenting with MHNO defined by Meigs A, Meigs B, and Wildman. Nonobese individuals with resistin and TNF-␣ concentrations in the bottom 50th percentile were more likely to present with MHNO defined by Karelis and Meigs B. Reduced WBC count was positively associated with metabolic health defined by Meigs A, Meigs B, and Wildman.
Discussion
In this study, we demonstrated that MHO and MHNO subjects presented with lower C3 concentrations and, depending on metabolic health definition, also lower levels of CRP, IL-6, TNF-␣, PAI-1, and WBCs and higher adiponectin concentrations.
Elevated circulating concentrations of C3, an acutephase response protein with a central role in the innate immune system, have been associated with obesity and increased cardiometabolic risk (22) . C3 concentrations are also elevated in lean and obese diabetic individuals relative to both their lean and obese nondiabetic counterparts (23) . In that study, C3 concentrations correlated with insulin, glucose, and insulin resistance, suggesting that metabolic perturbations such as hyperglycemia and insulin resistance augment C3-mediated inflammation, which is the case for other components of the inflammatory response (24) . We have reported novel genetic associations between C3 polymorphisms with MetS risk (25) , and that abdominal obesity and dietary fat (intake and composition) modulate the relationship between elevated plasma C3 concentrations, C3 genotype, and MetS risk (26) . Although the relationship between C3 concentrations and cardiometabolic health has been examined, this
has not yet been investigated in the context of the MHO phenotypes.
In the current work, C3 concentrations were consistently lower in the metabolically healthy individuals, regardless of BMI and criteria used to define metabolic health, and were associated with up to 3.5 times increased likelihood of presenting with metabolic health in both obese and nonobese individuals. The observed differences in C3 levels between MHO and MUO subjects are similar to those reported in incident ischemic event cases and noncases (27) and in smokers with and without coronary heart disease (28). Thus, our data suggest that C3 may be important in terms of characterizing metabolic health, screening for those at greatest cardiometabolic risk, and as we have shown C3 levels and genotype to be modulated by dietary fat potentially as a therapeutic or dietary intervention target.
Chronic low-grade inflammation plays a role in the pathogenesis of insulin resistance, with elevated circulating levels of CRP and proinflammatory cytokines such TNF-␣ and IL-6 associated with increased cardiometabolic risk (5) . Reduced CRP, IL-6, and TNF-␣ levels have been previously reported in MHO individuals (8 -11, 17) . However, most of these studies were conducted in obese women and did not examine nonobese individuals. We found lower CRP, IL-6, and TNF-␣ concentrations in MHO and MHNO individuals relative to their metabolically unhealthy counterparts. Furthermore, reduced levels of these biomarkers were associated with increased odds of MHO and MHNO according to most definitions. Differences in CRP, IL-6, and TNF-␣ levels between MHO and MUO individuals were greater than those reported between noncases and cases of myocardial infarction (29) and CVD in the Caerphilly study (CRP only) (30) . Given the central role of obesity in the pathogenesis of cardiometabolic disease, the adipose tissue-derived inflammatory mediators adiponectin, leptin, and resistin may also be particularly important. A small study of obese subjects undergoing bariatric surgery recently demonstrated that adipose tissue in MHO individuals is characterized by smaller fat cells, reduced macrophage infiltration, and a more favorable inflammatory profile (31) . These findings support the hypothesis that MHO adipose tissue has enhanced adipogenic capacity resulting in increased lipid storage and reduced metabolic dysfunction, such as insulin resistance and lipotoxicity. Only 1 previous MHO study examined adipocytokines and did not report any differences between obese subjects with or without the MetS (9). In the current study, adiponectin levels were higher among the metabolically healthy subjects, consistent with previous findings in MHO individuals (6, 7) , and were associated with 2.5 to 4 times greater likelihood of being MHNO and MHO, respectively. Differences in adiponectin concentrations between MHO and MUO subjects defined by Meigs A, Meigs B, and Wildman exceeded those between patients with and without CVD in the Cardiovascular Health Study and the British Regional Heart Study (32, 33) . Data from mouse models suggest that increased adiponectin levels promote metabolic flexibility of adipose tissue (34) . Thus, the raised levels observed in the MHO subjects may partly account for their ability to maintain proper metabolic function under metabolically challenging circumstances. No relationship between MHO and resistin levels was identified, and reduced leptin levels were positively associated with MHO defined by insulin resistance.
To our knowledge, only 2 studies have examined WBC in MHO individuals and reported conflicting findings (11, 35) . Although the latter small study did not detect any differences in WBC counts, the investigators observed significantly higher levels of natural killer and cytotoxic T lymphocytes in MHO subjects, which may protect against malignancy, infection, and metabolic disease (35) . We report elevated WBC counts among MHO and MHNO subjects. The magnitude of the differences in WBC counts between MHO and MUO individuals was greater than that reported between individuals with and without CVD (30) . Results from association studies examining PAI-1 levels and CVD are inconsistent (36, 37) . We identified lower PAI-1 concentrations among the MHO subjects, consistent with previous findings (9, 11). The differences between the MHO and MUO subjects were comparable to those noted in some but not all myocardial infarction case control studies (29, 36) . Collectively, our data suggest both physiologically and clinically significant differences in inflammatory profiles between MHO and MUO individuals. Our study has several strengths, including a high participation rate (67%), inclusion of questionnaires to assess dietary and lifestyle behaviors, and characterization of the largest range of inflammatory markers among MHO and MHNO phenotypes to date. Notwithstanding these strengths, this study must be viewed within the context of its limitations. The cross-sectional study design limited our ability to make an inference about the causal relationships between inflammatory status and MHO. BMI was used to classify subjects as obese. Because BMI does not discriminate between lean and fat body mass, persons of short stature or muscular build may be misclassified. Future work may benefit from direct measurement of body fat (BF) using dual-energy x-ray absorptiometry. The finding that approximately half of obese subjects are metabolically healthy when classified using dual-energy x-ray absorptiometry-derived BF%, compared to approximately one-third by BMI (38) , signals that caution also needs to be taken regarding how obesity should be defined. Furthermore, the duration of obesity, which may impact our findings, was unknown and should be examined in future studies.
Few prospective studies tracking the development of cardiometabolic disease and mortality in MHO subjects exist, and where follow-up has occurred, results have been conflicting (39, 40) . Previous prospective studies have considered the MHO phenotype as a static condition. However, it is possible that transition between MHO and MUO over the follow-up period, as well as a lack of a unique MHO definition, may account for conflicting findings regarding CVD and mortality outcomes. A recent longitudinal study found that persistent MHO status was associated with favorable cardiometabolic outcomes, but that MHO status was transient for one-third of subjects (41) , suggesting that metabolically unhealthy obesity is a progressive phenotype along which metabolically healthy obesity represents a dynamic intermediate stage. Consistent with these findings, Soriguer et al (42) recently reported that a substantial proportion of MHO subjects were no longer metabolically healthy after a 6-year followup, with 37% reclassified as MUO. The planned longitudinal follow-up of the Mitchelstown cohort will allow differences in disease incidence, transition between MHO and MUO status, and all-cause mortality risk according to the different metabolic health criteria to be ascertained.
Our findings are of public health and clinical significance. Obesity diagnosis, particularly of those at greatest cardiometabolic risk, requires improvement. Better understanding of the association between MHO status and inflammation may have implications for predicting those at greatest risk of developing the most serious obesityrelated complications. Furthermore, there is a clear need to develop new preventative and therapeutic strategies as well as evidence-based public health measures to attenuate disease development. Current obesity treatment guidelines do not distinguish between MHO and MUO individuals and recommend treatment for all obese individuals, starting with lifestyle intervention. Dietary and lifestyle interventions in MHO subjects are sparse and have produced conflicting results (10, 43) . Nevertheless, they highlight the potential benefits of differentiating MHO and MUO individuals. We have recently shown that assessing BF% and BMI to classify obesity may help identify individuals at greater cardiometabolic risk than BMI alone (44) . Those identified as obese using both tools had a more metabolically unhealthy profile and were not responsive to dietary intervention. It may be that the MUO subjects are simply metabolically overburdened and thus no longer dietary responsive, whereas the MHO subjects have greater metabolic flexibility to adapt to dietary changes. Therefore, stratification of obese individuals based on their metabolic health phenotype may be important in ascertaining the appropriate therapeutic or intervention strategy.
Epidemiological studies demonstrate anti-inflammatory effects of dietary fish, fish oil, and/or long chain n-3 polyunsaturated fatty acid (LC n-3 PUFA) consumption (45) . Using an in vitro coculture system we demonstrated that treatment with LC n-3 PUFAs attenuates the macrophage-induced proinflammatory phenotype and improves insulin sensitivity in adipocytes (46) . A recent review supports recommendations for regular fatty fish consumption, particularly in terms of reducing inflammation among adults with 1 or more MetS features (45) . In the current study, total and oily fish consumption and dietary fat composition were not different between MHO and MUO subjects (data not shown). Whether MHO individuals would derive particular benefit from dietary and/or lifestyle interventions aimed at reducing inflammation is unknown. The potential of dietary fatty acids to attenuate the transition from MHO to MUO status or indeed reversion from an unhealthy to a healthy metabolic state remains an intriguing possibility that would be worthwhile to address given the anti-inflammatory effects of LC n-3 PUFA.
In conclusion, the results of our study suggest that reduced inflammatory status increases the likelihood of metabolic health, particularly among obese subjects. Associations between inflammatory markers and metabolic 
